Immunomonitoring of Intravenous and Subcutaneous Anti-CD49d Treatment in Patients with Multiple Sclerosis (P7-6.009)
Alex Agundez Moreno, Silvia Presas, Aina Teniente‐Serra, Eva Martínez‐Cáceres et autres
To determine if CD49d receptor occupancy remains stable over time in patients that change from IV-NTZ to SC-NTZ either every four or six weeks.
es (code pays fourni par la source)